The impact of cigarette smoke exposure on the risk of colorectal neoplasia (CRN) in patients with inflammatory bowel disease (IBD) may differ according to IBD type, suggested results of a single-centre study presented at the recent Crohn’s and Colitis Congress 2021.
In patients undergoing surgery for inflammatory bowel disease (IBD), presurgical exposure to biologics was not associated with an increased risk of post-surgical infectious complications or surgical site infections, according to a study presented at the recent Crohn’s and Colitis Congress 2021.
One way the S1P* receptor modulator ozanimod reduces disease activity in patients with ulcerative colitis (UC) is by driving down biomarkers of intestinal inflammation such as faecal calprotectin (FCP) and faecal lactoferrin (FLF), according to the TOUCHSTONE study presented at the 2021 Crohn’s and Colitis Congress.
Exposure to anti-TNF therapy appears to be associated with an increased body mass index (BMI) z-score in paediatric patients with Crohn’s disease, according to a study presented at Crohn’s & Colitis Congress 2021.
Amiselimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator, demonstrated a favourable safety profile among healthy individuals, according to a phase I study presented at Crohn’s and Colitis 2021.
While children with inflammatory bowel disease (IBD) see their conditions improve with biologic therapy, those with ulcerative colitis (UC) tend to have residual disease activity even after clinical remission, according to two separate studies presented at the 2021 Crohn’s and Colitis Congress.